Detect an early-stage cancer save a patient and save a family
Detect an early-stage cancer save a patient and save a family
Focus on tumor DNA methylation detection
About Anouve
Established in 2021, Qingdao Anouve Biological Medical Technology Co. ,Ltd. is a scientific and innovative enterprise engaged in the research, development, production and sales of in vitro diagnostic reagents and supporting instruments. The products involve the auxiliary diagnosis, concomitant diagnosis and postoperative monitoring of tumor methylation; Detection of pathogenic nucleic acids such as helicobacter pylori and drug-resistant mutations; Guidance on accurate medication of inflammatory bowel disease; Automatic nucleic acid automatic nucleic acid sample pretreatment system, etc.
The highest goal of the company is to meet the needs of patients. Adhering to the value concept of diligence and pragmatism, we will lead the high-quality development of enterprises through innovation drive and provide better tools and technical support for medical workers through continuous R&D investment and technological innovation to better serve the health of patients. The company will make positive contributions to the cause of human health.
Company Advantages
-
Product Advantages
self-developed product system, independent intellectual property rights; Non-invasive molecular diagnostic products for digestive tract; CE certification, the performance meets the requirements of similar products of FDA
-
Team Advantages
continuous entrepreneurs and excellent scientists; More than twenty years of IVD marketing and channel construction accumulation; Experience in registration and approval of many similar products
-
Technical Advantages
the whole process automation closed overall solution; Realize early screening methylation of blood and feces double intestinal cancer; Constructing molecular diagnosis and treatment ecological circle of digestive tract diseases
Early detection of cancer is as simple as blood test
Compared with the expensive and invasive gastrointestinal endoscopy, liquid biopsy can accurately detect the expression of cancer cells or oncogenes with only 5 ~ 10 ml of blood of the patient, which has the advantages of non-invasive, repetitive acquisition of tumor samples, small side effects, fast detection speed, timely response to the dynamic changes of tumors, etc., so as to realize easy blood withdrawal and early tumor screening.
Enterprise Dynamics
-
2023-12-15
Specific experimental steps for methylation detection method
-
2023-12-15
One article will help you understand DNA methylation!
-
2023-12-15
A New Tool for Early Screening of Tumors - Methylation Detection Technology
-
2023-12-15
Science Popularization | Age of Early Screening for Cancer - Principles and Sign
